stockrowTG Therapeutics, Inc.
TGTX Healthcare Biotechnology
TG Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $616.3 million, up 87.3% from fiscal 2024.
- Revenue
- +70.3%
- EPS
- −73.7%
- Free cash flow
- +427.1%
- Total debt
- +204.2%
Quarter to June 2026, against a year earlier
Follow TGTX
Alert me
TG Therapeutics, Inc. (TGTX) Net income
TG Therapeutics, Inc.'s net income for fiscal 2025 was $447.2M, up 1,812.4% from $23.4M in fiscal 2024. Over the twelve months to 30 June 2026 it was $441.5M. Over the past ten years it has ranged from −$348.1M (fiscal 2021) to $447.2M (fiscal 2025) — the current reading is the highest in ten years. Net income has risen for 4 consecutive fiscal years. TG Therapeutics, Inc. ranks 13th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $447.2M | 1,812.41% |
| FY2024 | $23.4M | 84.52% |
| FY2023 | $12.7M | — |
| FY2022 | −$223.8M | — |
| FY2021 | −$348.1M | — |
| FY2020 | −$279.4M | — |
| FY2019 | −$172.9M | — |
| FY2018 | −$173.5M | — |
| FY2017 | −$118.5M | — |
| FY2016 | −$78.3M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $7.8M | (60.66%) |
| Mar 2026 | $19.8M | (14.15%) |
| Dec 2025 | $23.0M | (94.11%) |
| Sep 2025 | $390.9M | 1,286.79% |
| 42 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| TGTX TG Therapeutics, Inc. | $441.5M |
| KRYS Krystal Biotech, Inc. compare | $225.2M |
| CAI Caris Life Sciences,�Inc. compare | $96.1M |
| PTGX Protagonist Therapeutics, Inc. compare | $82.9M |
| TWST Twist Bioscience Corporation compare | −$136.7M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$155.5M |
| SYRE Spyre Therapeutics, Inc. compare | −$263.9M |
| CYTK Cytokinetics, Incorporated compare | −$777.9M |
| IBRX ImmunityBio, Inc. compare | −$992.4M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on TGTX
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement